Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Neuroendocrine Tumor

Neuroendocrine Tumor

Part of Germ cell tumors

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Neuroendocrine Tumor

47 trials tracked for Neuroendocrine Tumor: 10 in phase 3 or 4 and 4 with published results. The most-cited published study has 1261 citations.

47Trials tracked
10Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 4 Phase 3 6 Phase 2 33 Phase 1 2 Other / NA 2
  1. Phase 3 Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) Completed · 1,261 cited
  2. Phase 4 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed · 65 cited
  3. Phase 4 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Completed · 5 cited
  4. Phase 3 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas Completed · 4 cited
  5. Phase 4 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) Completed
  6. Phase 4 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Completed
Show 41 more trials
  1. Phase 3 Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan Completed
  2. Phase 3 Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE Completed
  3. Phase 3 Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor Completed
  4. Phase 3 Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Completed
  5. Phase 2 Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Completed
  6. Phase 2 Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors Completed
  7. Phase 2 A Study of Pembrolizumab in Patients With Neuroendocrine Tumors Completed
  8. Phase 2 A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors Completed
  9. Phase 2 Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Completed
  10. Phase 2 RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) Completed
  11. Phase 2 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors Completed
  12. Phase 2 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed
  13. Phase 2 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed
  14. Phase 2 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed
  15. Phase 2 Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Completed
  16. Phase 2 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Completed
  17. Phase 2 Cabozantinib and Nivolumab for Carcinoid Tumors Completed
  18. Phase 2 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed
  19. Phase 2 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Completed
  20. Phase 2 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Completed
  21. Phase 2 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin Completed
  22. Phase 2 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors Completed
  23. Phase 2 Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT Completed
  24. Phase 2 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed
  25. Phase 2 Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors Completed
  26. Phase 2 A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer Completed
  27. Phase 2 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed
  28. Phase 2 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed
  29. Phase 2 Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours. Completed
  30. Phase 2 Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Completed
  31. Phase 2 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Completed
  32. Phase 2 Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors Completed
  33. Phase 2 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed
  34. Phase 2 A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours Completed
  35. Phase 2 Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Completed
  36. Phase 2 Lithium for Low-Grade Neuroendocrine Tumors Completed
  37. Phase 2 Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors Completed
  38. Phase 1 Study of Everolimus (RAD001) in Combination With Lenalidomide Completed
  39. Phase 1 Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors Completed
  40. N/A Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors Completed
  41. N/A Dual-Tracer Theranostic PET Completed

Showing the 47 most-cited and recently-updated of 47 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Neuroendocrine Tumor: what the trials found

Axitinib demonstrated a statistically significant improvement in Objective Response Rate (ORR) compared to the control group (p=0.007) 1. However, Axitinib did not show statistically significant differences in Progression-Free Survival (PFS) 1 or Biochemical Response 1.

Everolimus demonstrated a statistically significant improvement in the probability of participants remaining event-free in PFS based on central radiology assessment (p=<0.001) 6. Other studies evaluating Everolimus showed a 47% rate of hepatic progression-free survival at 24 months 20, though other metrics such as overall survival and first/second progression-free survival did not reach statistical significance in those specific trials [6, 7].

Nivolumab was evaluated in two studies; one reported a 54.1% overall survival rate at 12 months 17. Other established interventions include Octreotide (including long-acting release) [3, 10], Pasireotide 4, and various imaging agents such as 64Cu-DOTATATE 8 and 68Ga-DOTATOC 9.

RAD001 showed a 44.9% ORR and a 73.5% disease control rate 2.

Recent results — preliminary, needs further review

  • Lenvatinib was evaluated in a Phase 2 trial 11.

For the clinician treating this condition

  • Axitinib provides a statistically significant improvement in Objective Response Rate (ORR) but does not significantly impact PFS or biochemical response 1.
  • Everolimus shows significant improvement in progression-free survival based on central radiology assessment 6 and maintains hepatic progression-free survival at 24 months 20.
  • Nivolumab has been established in clinical trials with a reported 12-month overall survival rate of 54.1% 17.

AI synthesis of 9 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review offers practical recommendations for implementing PET-guided therapy workflows in clinical practice
Oncology Sys. Review
Narrative review offers practical recommendations for implementing PET-guided therapy workflows in clinical practice PET scans now guide your radiation treatment
This narrative review synthesizes evidence regarding the implementation of PET-guided therapy workflows.
Imagine standing in a doctor's office waiting for radiation therapy.
Frontiers Apr 23, 2026
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs
Oncology RCT
Phase II RCT finds no benefit for adding capecitabine to 177Lu-Dotatate in advanced NETs Adding a Drug Actually Hurted These Patients
A Phase II randomized controlled trial in 111 patients with advanced somatostatin receptor-positive GEP or bronchopulmonary NETs compared…
Adding a common chemotherapy drug to cancer treatment actually made tumors grow faster and reduced survival time for these patients.
Apr 16, 2026

Research across Germ cell tumors

Related studies from across the Germ cell tumors family.

Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial
Oncology RCT
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial New Combo Shows Modest Promise for Hard-to-Treat Neuroendocrine Cancers
This randomized phase II trial enrolled 185 patients with advanced neuroendocrine carcinoma refractory to platinum-based chemotherapy.
For patients with rare, aggressive neuroendocrine cancers that resist initial treatment, this study offers a new, though modest, combination…
Apr 23, 2026